Trial Profile
Determination of the human papillomavirus (HPV)-specific antibody status in oral fluids of individuals vaccinated with a quadrivalent HPV vaccine.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Apr 2013
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Therapeutic Use
- 20 Apr 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 01 Aug 2011 New trial record